Transfection News and Research

RSS

Covaris launches Bench-top SF220 Formulation Processing System

Covaris Incorporated today announced the introduction of the Bench-top SF220 High Performance Formulation Processing System.

25 Mar 2011

PET imaging may play a role in early evaluation of vandetanib response in thyroid cancer

Positron emission tomography can image metabolic changes following treatment with the protein kinase inhibitor vandetanib, helping to define the therapy response or the effectiveness of the therapeutic agent, according to research published in the February issue of The Journal of Nuclear Medicine.

1 Feb 2011

Novel AAV gene therapy offers various advantages

A new, simplified method for producing large amounts of viral vector cassettes capable of shuttling genes into host cells will help advance the promising field of gene therapy as applications move into large animal studies and human clinical trials.

6 Jan 2011

Nacalai to distribute Techulon's Glycofect Transfection Reagent platform products in Japan

Techulon Inc., an early stage life sciences company has signed an agreement with Nacalai USA, Inc. and its parent company Nacalai Tesque, Inc. for distribution of its Glycofect Transfection Reagent platform products in Japan. Glycofect is a polymeric transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used by government, university and corporate laboratories around the world for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.

9 Dec 2010

Roche introduces X-tremeGENE 9, X-tremeGENE HP reagents

Roche announced today the introduction of two new high-performance DNA transfection reagents for its innovative cellular analysis portfolio for life science research.

7 Dec 2010

Life Technologies launches Qubit 2.0 Fluorometer for molecular biology research

Life Technologies Corporation, a provider of innovative life science solutions, today announced the launch of its next-generation Qubit® 2.0 Fluorometer specifically for molecular biology researchers who work with precious samples and perform applications that require a large financial or time investment. The new system quantitates DNA, RNA and protein with accuracy, sensitivity, speed and ease-of-use.

29 Nov 2010

Techulon signs exclusive license with Virginia Tech to market new theranostic transfection reagent

Techulon™ Inc., an early stage life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new theranostic transfection reagent. This new traceable reagent complements Techulon's currently marketed Glyocofect™ transfection platform and expands the company's offering in an $800 million market that is steadily growing at 15% annually.

26 Oct 2010

Techulon signs license with Virginia Tech Intellectual Properties to market DNA delivery platform

Techulon Inc., a life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new, traceable DNA delivery platform created to deliver genetic medicine to cells while carrying a beacon so scientists can follow its progress.

22 Oct 2010

Altogen Biosystems releases PEG-Liposome siRNA In Vivo Transfection Kit

Altogen Biosystems announced the release of its second generation of in vivo RNAi transfection reagent in the company's popular in vivo delivery product line: PEG-Liposome siRNA In Vivo Transfection Kit. This reagent is also compatible for in vivo transfection of other negatively charged molecules – RNA, DNA, and small proteins.

22 Oct 2010

Study demonstrates potential of nontoxic envelope proteins as an alternative to pseudotype lentiviral vectors

Therapeutic lentiviral vectors are emerging as vital tools for molecular medicine as evidenced by the growing number of clinical trials using these vector systems. From a basic research standpoint, lentiviral vectors are very intriguing substrates. On the one hand, the HIV-1 genome offers expanded cloning capacity and the capability to transduce nondividing cells such as hematopoietic stem cells (HSCs) and neurons.

4 Oct 2010

Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapies

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.

30 Sep 2010

FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011.

23 Sep 2010

Promega to provide FuGENE HD Transfection Reagent throughout life science market

Promega Corporation announces it will provide FuGENE HD Transfection Reagent throughout the life science market. The comprehensive, direct use offering from Promega means any life scientist can utilize FuGENE technology with no licensing requirements. FuGENE HD enables the transfection of DNA into many cell types with high efficiency and little-to-no toxicity.

2 Sep 2010

Mirus Bio launches new TransIT-PRO transfection kit for biotherapeutic protein production

Mirus Bio now offers a new transfection kit ideal for biotherapeutic protein production in large pharma and biotech settings. Mirus Bio's new TransIT-PRO™ Kit will decrease time to produce usable protein by maximizing target protein yields through transient transfection.

19 Aug 2010

Life Technologies, CEVEC Pharmaceuticals sign licensing agreement to supply CAP-T expression kits

CEVEC Pharmaceuticals, the developer of a novel human protein expression system derived from amniocytes, announced today the signing of a co-exclusive worldwide licensing agreement with Life Technologies Corporation, a leading provider of innovative life science solutions based in Carlsbad, California. Under the terms of the agreement, Life Technologies and CEVEC will co-operate to offer optimized expression kits based on CEVEC's proprietary CAP-T cells to the global life science research community.

18 Aug 2010

Clontech Laboratories, TET Systems expand license agreement

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., and TET Systems (TET), a privately-held German biotech company based in Heidelberg, today announced that they have signed an amendment to their existing license agreement. Under the expanded license agreement, Clontech obtains rights to develop, manufacture and commercialize novel Tet Systems products as the Tet-On® 3G™ Inducible Expression System.

26 Jul 2010

Gene therapy holds promise in treating cancer, cardiovascular and neurodegenerative diseases

EUREKA project E! 3371 Gene Transfer Agents has made great advances in the development of novel non-viral carriers able to introduce genetic material into the target cells.

25 Jun 2010

Vandetanib extends Progression Free Survival in ZETA phase III study for advanced medullary thyroid cancer

Results from ZETA, a phase III study in patients with advanced medullary thyroid cancer (MTC), showed that treatment with the investigational drug vandetanib significantly extended Progression Free Survival (PFS), the primary endpoint of the study, by demonstrating a 54% reduction in the rate of progression compared to placebo.

8 Jun 2010

MaxCyte STX Scalable Transfection System acquired by CCS Cell Culture Service

MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, is pleased to announce that CCS Cell Culture Service GmbH has acquired the MaxCyte® STX™ Scalable Transfection System to develop and optimize cells for the pharmaceutical industry.

12 May 2010

Goodwin Biotechnology, Hyprocell sign collaborative agreement to strengthen clinical development services

Goodwin Biotechnology Inc., a full service contract biomanufacturing company, and Hyprocell LLC, a clinical cell line development services company, jointly announced today their collaborative agreement to create a business model enabling customers to access their one stop shop services.

28 Apr 2010